CRISPR Therapeutics AG (CRSP): Price and Financial Metrics


CRISPR Therapeutics AG (CRSP): $121.25

3.44 (+2.92%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CRSP to Watchlist
Sign Up

Industry: Biotech


Ranked

of 504

in industry

CRSP POWR Grades


  • Value is the dimension where CRSP ranks best; there it ranks ahead of 89.01% of US stocks.
  • The strongest trend for CRSP is in Momentum, which has been heading down over the past 48 weeks.
  • CRSP ranks lowest in Stability; there it ranks in the 4th percentile.

CRSP Stock Summary

  • With a year-over-year growth in debt of 280.71%, CRISPR Therapeutics AG's debt growth rate surpasses 96.56% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, CRISPR Therapeutics AG is reporting a growth rate of 2,089.77%; that's higher than 98.75% of US stocks.
  • As for revenue growth, note that CRSP's revenue has grown 211.87% over the past 12 months; that beats the revenue growth of 96.63% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to CRISPR Therapeutics AG are ARGX, FATE, NKTR, RAPT, and ATRA.
  • Visit CRSP's SEC page to see the company's official filings. To visit the company's web site, go to www.crisprtx.com.

CRSP Valuation Summary

  • CRSP's EV/EBIT ratio is 17.8; this is 39.25% lower than that of the median Healthcare stock.
  • Over the past 59 months, CRSP's EV/EBIT ratio has gone up 26.5.
  • Over the past 59 months, CRSP's EV/EBIT ratio has gone up 26.5.

Below are key valuation metrics over time for CRSP.

Stock Date P/S P/B P/E EV/EBIT
CRSP 2021-08-31 10.6 3.7 21.3 17.8
CRSP 2021-08-30 10.2 3.5 20.6 17.1
CRSP 2021-08-27 10.5 3.6 21.1 17.6
CRSP 2021-08-26 10.3 3.6 20.8 17.3
CRSP 2021-08-25 10.6 3.7 21.5 18.0
CRSP 2021-08-24 10.7 3.7 21.6 18.1

CRSP's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CRSP has a Quality Grade of C, ranking ahead of 72.29% of graded US stocks.
  • CRSP's asset turnover comes in at 0.441 -- ranking 102nd of 677 Pharmaceutical Products stocks.
  • CDTX, SEEL, and RGRX are the stocks whose asset turnover ratios are most correlated with CRSP.

The table below shows CRSP's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.441 1 0.579
2021-03-31 0.001 1 -0.839
2020-12-31 0.001 1 -1.179
2020-09-30 0.067 1 -1.230
2020-06-30 0.301 1 0.242
2020-03-31 0.352 1 0.539

CRSP Price Target

For more insight on analysts targets of CRSP, see our CRSP price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $162.94 Average Broker Recommendation 1.55 (Moderate Buy)

CRSP Stock Price Chart Interactive Chart >

Price chart for CRSP

CRSP Price/Volume Stats

Current price $121.25 52-week high $220.20
Prev. close $117.81 52-week low $79.31
Day low $116.91 Volume 772,200
Day high $122.25 Avg. volume 1,626,022
50-day MA $123.43 Dividend yield N/A
200-day MA $135.01 Market Cap 9.24B

CRISPR Therapeutics AG (CRSP) Company Bio


CRISPR Therapeutics AG focuses on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. The company is based in Basel, Switzerland.


CRSP Latest News Stream


Event/Time News Detail
Loading, please wait...

CRSP Latest Social Stream


Loading social stream, please wait...

View Full CRSP Social Stream

Latest CRSP News From Around the Web

Below are the latest news stories about CRISPR Therapeutics AG that investors may wish to consider to help them evaluate CRSP as an investment opportunity.

Genome Editing Market Size To Reach USD 15072.3 Million by 2025 | Top Key Players Sangamo Therapeutics, ToolGen, Vertex, CRISPR Therapeutics, Precision Biosciences, Oxford Genetics

Global Genome Editing Market is valued at USD 5052.2 Million in 2020 and expected to reach USD 15072.3 Million by 2025 with the CAGR of 16.9% over the forecast period. Global Genome Editing Market: Global Size, Trends, Competitive, Historical & Forecast

OpenPR | September 22, 2021

CRISPR Therapeutics AG (CRSP) Gains But Lags Market: What You Should Know

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $117.81, moving +0.48% from the previous trading session.

Yahoo | September 22, 2021

Top Biotech Stocks for Q4 2021

The biotechnology industry includes companies that develop drugs and diagnostic technologies for the treatment of diseases and medical conditions. This means that investors may wait for years before knowing whether a drug under development will pay off. Many biotech companies have shifted their focus entirely or added COVID-19 vaccine and treatments to their product pipeline.

Yahoo | September 20, 2021

Why CRISPR Therapeutics AG (CRSP) is a Top Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.

Yahoo | September 17, 2021

Is Now The Time To Put CRISPR Therapeutics (NASDAQ:CRSP) On Your Watchlist?

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Yahoo | September 16, 2021

Read More 'CRSP' Stories Here

CRSP Price Returns

1-mo -3.62%
3-mo -14.92%
6-mo 9.00%
1-year 45.54%
3-year 161.48%
5-year N/A
YTD -20.81%
2020 151.39%
2019 113.18%
2018 21.68%
2017 15.89%
2016 N/A

Continue Researching CRSP

Here are a few links from around the web to help you further your research on CRISPR Therapeutics AG's stock as an investment opportunity:

CRISPR Therapeutics AG (CRSP) Stock Price | Nasdaq
CRISPR Therapeutics AG (CRSP) Stock Quote, History and News - Yahoo Finance
CRISPR Therapeutics AG (CRSP) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9939 seconds.